Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines

M. Hotze, H. Baurecht, E. Rodríguez, N. Chapman-Rothe, M. Ollert, R. Fölster-Holst, J. Adamski, T. Illig, J. Ring, S. Weidinger*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

79 Citations (Scopus)

Abstract

Omalizumab, a monoclonal antibody targeting IgE, is an established therapy for severe allergic asthma and has shown efficacy in chronic spontaneous urticaria. Small-scale studies indicated some beneficial effect also in atopic dermatitis (AD). To evaluate the efficacy of omalizumab in AD and to identify markers associated with treatment response, we conducted a prospective 28-week open-label trial on 20 adults with moderate-to-severe AD. Our results confirm previous observations of a positive response in a subgroup of patients and suggest that responders are characterized by the absence of filaggrin mutations and altered lipid metabolite profiles with high levels of various glycerophospholipids.

Original languageEnglish
Pages (from-to)132-135
Number of pages4
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume69
Issue number1
DOIs
Publication statusPublished - Jan 2014
Externally publishedYes

Keywords

  • anti-IgE
  • atopic dermatitis
  • filaggrin
  • metabolomics
  • omalizumab

Fingerprint

Dive into the research topics of 'Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines'. Together they form a unique fingerprint.

Cite this